Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran in Children With Homozygous Familial Hypercholesterolemia (ORION-19)
NCT06597006Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Feb 2025
- Primary completion
- Mar 2028
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 11
01
Overview
A Phase 3 trial of inclisiran in familial hypercholesterolemia (FH), sponsored by Novartis. Started Feb 2025; status: recruiting.
02
Drugs
inclisiran
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NCT06597006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06597006.